Every Form 4 that Tectonic Therapeutic, Inc. (TECX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TECX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TECX filings page.
Tectonic Therapeutic, Inc. Chief Financial Officer Daniel Lochner had 520 common shares withheld by the issuer on September 25, 2026, to satisfy tax-withholding obligations tied to restricted stock unit vesting and settlement. The reported price was $23.67 per share, and his direct holdings afterward were 58,024 shares. No Rule 10b5-1 plan is reported.
Tectonic Therapeutic, Inc. (TECX) Chief Scientific Officer Peter McNamara reported selling 536 shares on September 30, 2026, at a weighted average price of $23.04 per share; the shares sold in transactions ranging from $22.61 to $23.32. The sale was made under a Rule 10b5-1 trading plan adopted November 14, 2025. On September 25, 2026, the issuer withheld 444 shares to satisfy his tax withholding obligations from vesting and settlement of restricted stock units granted September 25, 2025; the reported transaction price was $23.67 per share.
Tectonic Therapeutic, Inc. Chief Medical Officer Marcella K. Ruddy had 525 common shares withheld by the issuer on September 25, 2026, to satisfy tax-withholding obligations tied to the vesting and settlement of restricted stock units granted September 25, 2025. The reported price was $23.67 per share; she directly held 67,157 shares after the transaction.
Tectonic Therapeutic, Inc. (TECX) reported that CEO Alise Reicin had 1,545 common shares withheld by the issuer on September 25, 2026, to satisfy tax-withholding obligations connected with vesting and settlement of restricted stock units granted on September 25, 2025. The reported price was $23.67 per share. After the transaction, her reported direct holdings were 309,078 common shares. As of September 25, 2026, the Reicin-Boiarsky Family Trust held 127,030 common shares.
Tectonic Therapeutic, Inc. Chief Business Officer Marc Schwabish had 411 shares withheld by the issuer on September 25, 2026, to satisfy tax-withholding obligations tied to vesting and settlement of restricted stock units granted on September 25, 2025. He directly held 44,903 shares following the transaction; the reported price was $23.67 per share.
Tectonic Therapeutic, Inc. (TECX) reported that Chief Business Officer Marc Schwabish received a grant of 17,750 employee stock options on September 3, 2026. The options have an exercise price of $29.92 per share, expire on September 2, 2036, and cover 17,750 shares of common stock.
According to the vesting terms, 1/8 of the options vest on September 3, 2026, with the remaining options vesting in 42 equal monthly installments beginning October 3, 2026, subject to his continued service to the company on each vesting date. No Rule 10b5-1 trading plan is reported.
Tectonic Therapeutic, Inc. (TECX) reported that Chief Scientific Officer Peter McNamara received a grant of stock options for 21,000 shares of common stock on September 3, 2026. The options have an exercise price of $29.92 per share and expire on September 2, 2036. One-eighth of the options vest on September 3, 2026, with the remainder vesting in 42 equal monthly installments beginning October 3, 2026, subject to his continued service. No transactions were made under a Rule 10b5-1 trading plan, and McNamara now holds 21,000 options directly from this award.
Tectonic Therapeutic, Inc. (TECX) reported that Chief Financial Officer Daniel Lochner received a grant of 24,250 employee stock options on September 3, 2026. The options have an exercise price of $29.92 per share and expire on September 2, 2036. According to the vesting terms, 1/8 vests on September 3, 2026, with the remaining shares vesting in 42 equal monthly installments beginning October 3, 2026, subject to his continued service.
Tectonic Therapeutic, Inc. (TECX) reported that its Chief Medical Officer, Marcella K. Ruddy, received a grant of 24,250 Employee Stock Options on September 3, 2026, each with an exercise price of $29.92 per share and expiring on September 2, 2036.
The options cover 24,250 shares of Common Stock and are held directly. According to the vesting terms, 1/8 of the options vest on September 3, 2026, with the remaining options vesting in 42 equal monthly installments beginning on October 3, 2026, subject to Dr. Ruddy’s continued service to Tectonic Therapeutic on each vesting date.
Tectonic Therapeutic, Inc. (TECX) reported that Chief Executive Officer and director Alise Reicin received a grant of employee stock options covering 69,250 shares of common stock on September 3, 2026. The options have an exercise price of $29.92 per share and expire on September 2, 2036.
According to the vesting terms, 1/8 of the options vest on September 3, 2026, with the remaining shares vesting in 42 equal monthly installments beginning on October 3, 2026, subject to her continued service with the company. No Rule 10b5-1 trading plan is reported in connection with this award.
Tectonic Therapeutic, Inc. (TECX) reported that Chief Scientific Officer Peter McNamara exercised options and sold shares on August 25, 2026 under a Rule 10b5-1 trading plan. He exercised 43 options at an exercise price of $14.71 per share into 43 shares of common stock, then sold those 43 common shares in a sale transaction at $36.52 per share. Following the exercise, 7,787 stock options remained outstanding from this grant, which vests in 48 equal monthly installments beginning October 25, 2025.
Tectonic Therapeutic, Inc. Chief Scientific Officer Peter McNamara exercised options for 43 shares of common stock at an exercise price of $14.71 per share and immediately sold 43 shares of common stock at $35.00 per share on August 12, 2026. Following the option exercise, he held 7,830 employee stock options directly. The exercise and subsequent sale were carried out under a Rule 10b5-1 trading plan adopted on November 14, 2025.
Tectonic Therapeutic Chief Scientific Officer Peter McNamara exercised options for 172 shares of common stock at $14.71 per share and the same day sold 172 shares in an open-market trade at $35.00 per share under a pre-arranged Rule 10b5-1 plan. Following these transactions, he directly holds 55,285 common shares and 7,873 employee stock options, indicating a small, routine liquidity event relative to his overall position.
Tectonic Therapeutic, Inc. Chief Executive Officer Alise Reicin reported routine share movements related to equity compensation. The company withheld 924 shares of Common Stock at $30.34 per share to cover her tax obligations when restricted stock units granted on December 4, 2024 vested and settled. After this tax-withholding disposition, she directly holds 310,623 shares of Common Stock. A separate entry shows 127,030 shares held indirectly through the Reicin-Boiarsky Family Trust, where she may share voting and dispositive power but disclaims beneficial ownership beyond her pecuniary interest. These events reflect compensation mechanics rather than open-market buying or selling.
Tectonic Therapeutic, Inc. reported that Chief Financial Officer Daniel Lochner received a grant of performance stock options covering 7,500 shares of common stock. The options have an exercise price of $16.80 per share, expire on June 19, 2034, and are fully vested and immediately exercisable as of June 1, 2026. The 7,500 shares represent 50% of a larger performance-based award already earned after the board certified certain performance goals, while the remaining 50% will be earned only if additional performance criteria are met.
Tectonic Therapeutic, Inc. reported that director and 10% owner Timothy A. Springer received a grant of stock options covering 10,200 shares of common stock. The options have an exercise price of $28.56 per share and expire on June 8, 2036.
The award vests in full on the earliest of June 9, 2027, the company’s 2027 annual stockholder meeting, or a defined change in control, provided he continues to serve the company through that date.
Tectonic Therapeutic, Inc. director Praveen P. Tipirneni received a grant of stock options covering 10,200 shares of common stock at an exercise price of $28.56 per share. These options were awarded as a compensation grant, not an open-market purchase or sale.
The options vest in full on the earliest of June 9, 2027, the company’s 2027 annual meeting of stockholders, or a qualifying change in control, as long as the director continues providing service through that date. After this grant, the reported derivative holdings in this award total 10,200 options.
Tectonic Therapeutic, Inc. director Phillip B. Donenberg reported a compensation-related equity award. He received a stock option to acquire 10,200 shares of common stock at an exercise price of $28.56 per share, giving him the right, but not the obligation, to buy company stock at that price.
The option vests in full on the earliest of June 9, 2027, the company’s 2027 annual stockholder meeting, or a qualifying change in control, as long as he continues serving the company through that date. Following this grant, he holds 10,200 stock options directly, with an expiration date in 2036.
Tectonic Therapeutic, Inc. director Stefan Vitorovic received a grant of stock options covering 10,200 shares of common stock. The options have an exercise price of $28.56 per share and expire on June 8, 2036, bringing his option holdings to 10,200 shares.
According to the terms, the award vests in full on the earliest of June 9, 2027, the company’s 2027 annual stockholder meeting, or a qualifying change in control, in each case only if he continues providing service to the company through that date.
Tectonic Therapeutic, Inc. reported that director Jessica Caroline Chutter received a grant of stock options covering 20,400 shares of common stock. The options have an exercise price of $29.10 per share and expire on June 7, 2036.
According to the vesting terms, one-third of the option shares will vest on June 8, 2027, with the remaining shares vesting in 24 equal monthly installments after that date, subject to Ms. Chutter’s continued service with the company. Following this grant, she holds 20,400 stock options directly.
Tectonic Therapeutic, Inc. Chief Medical Officer Marcella K. Ruddy reported an open-market sale of 1,065 shares of Common Stock at $30.00 per share on May 4, 2026. Following this transaction, she directly holds 67,682 shares of the company’s Common Stock. The sale was executed under a Rule 10b5-1 trading plan adopted on April 8, 2025, indicating it was pre-arranged rather than a discretionary trade.
Tectonic Therapeutic, Inc. Chief Medical Officer Marcella K. Ruddy executed an open-market sale of 1,000 shares of Common Stock at $31.05 per share on April 1, 2026. She held 68,747 shares afterward, and the sale was made under a pre-established Rule 10b5-1 trading plan.
Tectonic Therapeutic, Inc. director Nader Francois received a grant of stock options covering 20,400 shares of common stock. The options have an exercise price of $30.78 per share and expire on March 31, 2036.
One third of the option vests on April 1, 2027, with the remaining two thirds vesting in 24 equal monthly installments, as long as Francois continues to provide service through each vesting date. Following this grant, the filing shows 20,400 derivative securities held directly.
Tectonic Therapeutic, Inc. Chief Medical Officer Marcella K. Ruddy reported an open-market sale of 10,000 shares of common stock on March 6, 2026 at a price of $30.00 per share. After this transaction, she directly holds 69,747 shares of the company’s common stock.
The sale was executed under a Rule 10b5-1 trading plan that she adopted on April 8, 2025, indicating the trades were pre-arranged under that plan rather than timed at her discretion.
Tectonic Therapeutic, Inc. Chief Scientific Officer Peter McNamara reported option exercises and share sales on March 6, 2026. He exercised employee stock options for 2,500 and 215 shares, which converted into common stock at exercise prices of $2.3800 and $14.7100 per share.
On the same date, he sold 6,047 shares of common stock at $30.0000 per share and 215 shares at $35.0000 per share in open‑market transactions. After these trades, he directly owned 55,285 shares of Tectonic Therapeutic common stock. The filing notes these exercises and sales were made under a Rule 10b5‑1 trading plan adopted on November 14, 2025.
REICIN ALISE reported acquisition or exercise transactions in this Form 4 filing.
Tectonic Therapeutic, Inc. director and Chief Executive Officer Alise Reicin reported equity awards and updated holdings. On March 4, 2026, she was granted an employee stock option for 69,250 shares and a grant of 76,500 shares of common stock represented by restricted stock units.
The restricted stock units vest in three equal annual installments on March 4, 2027, March 4, 2028 and March 4, 2029, subject to her continued service. The option vests in 48 equal monthly installments beginning on April 4, 2026, also subject to continued service.
The filing also notes 127,030 shares of common stock held indirectly through the Reicin-Boiarsky Family Trust, where her spouse is a co-trustee and she may share voting and dispositive power, while disclaiming beneficial ownership beyond any pecuniary interest.
Schwabish Marc reported acquisition or exercise transactions in this Form 4 filing.
Tectonic Therapeutic, Inc. Chief Business Officer Marc Schwabish reported receiving new equity awards in the form of stock options and restricted stock units. On March 4, 2026, he was granted 17,750 employee stock options and 19,500 shares of common stock represented by restricted stock units.
The restricted stock units each correspond to one share of common stock and are scheduled to vest in three equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029, subject to his continued service. The stock options vest in 48 equal monthly installments beginning on April 4, 2026, also conditioned on continued service.
Tectonic Therapeutic, Inc. Chief Scientific Officer Peter McNamara reported a mix of equity awards and share sales. On March 4, 2026, he received an option grant for 21,000 shares at $0.0000 per share, vesting in 48 equal monthly installments beginning April 4, 2026, subject to continued service.
He also acquired 23,000 shares of common stock in the form of restricted stock units, each representing one share, vesting in three equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029, also subject to continued service. The filing shows open‑market sales of 1,649 shares at $22.06 on March 3, 2026 and 1,650 shares at $25.00 on March 4, 2026, pursuant to a Rule 10b5‑1 trading plan adopted on November 14, 2025. Following these transactions, he directly owned 58,832 common shares.
Lochner Daniel reported acquisition or exercise transactions in this Form 4 filing.
Tectonic Therapeutic, Inc. Chief Financial Officer Daniel Lochner reported equity awards on March 4, 2026. He received 26,500 shares of common stock in the form of restricted stock units that vest in three equal annual installments on March 4, 2027, March 4, 2028 and March 4, 2029, contingent on continued service. He was also granted an employee stock option for 24,250 shares, vesting in 48 equal monthly installments beginning on April 4, 2026, also subject to continued service, bringing his directly held common stock to 58,544 shares after the award.
Ruddy Marcella K. reported acquisition or exercise transactions in this Form 4 filing.
Tectonic Therapeutic, Inc. Chief Medical Officer Marcella K. Ruddy reported equity awards on March 4, 2026. She received 26,500 shares of common stock in the form of restricted stock units that vest in three equal annual installments on March 4, 2027, 2028 and 2029, subject to continued service. She was also granted an option for 24,250 shares, vesting in 48 equal monthly installments beginning April 4, 2026. Following these awards, her directly held common stock totaled 79,747 shares.
Tectonic Therapeutic, Inc. director and Chief Executive Officer Alise Reicin reported that the Reicin-Boiarsky Family Trust, a trust associated with her, bought 2,500 shares of common stock in an open-market purchase on February 11, 2026 at a weighted average price of $21.10 per share.
Following this transaction, the trust holds 127,030 shares with indirect ownership attributed to Reicin, while she also directly owns 235,047 shares of common stock.
Tectonic Therapeutic, Inc. Chief Executive Officer and director Alise Reicin reported an open-market purchase of 2,500 shares of common stock on February 11, 2026. The shares were bought at a weighted average price of $21.10 per share, with individual trades ranging from $21.02 to $21.15.
Following this transaction, Reicin directly holds 237,547 common shares. In addition, 124,530 common shares are held indirectly by the Reicin-Boiarsky Family Trust, where her spouse is a co-trustee. She may be deemed to share voting and dispositive power over the trust’s shares but disclaims beneficial ownership beyond her pecuniary interest.
Tectonic Therapeutic, Inc. reported an insider stock option exercise by Chief Business Officer Marc Schwabish. On February 10, 2026, he exercised an employee stock option for 4,500 shares of common stock at an exercise price of $2.38 per share.
Following this transaction, Schwabish directly owned 25,814 shares of common stock and held 82,014 employee stock options. The option originally vested beginning March 15, 2022, with remaining shares vesting in equal monthly installments over 36 months, subject to continued service.
Tectonic Therapeutic, Inc. Chief Financial Officer Daniel Lochner reported an open-market purchase of 6,000 shares of the company’s common stock on February 10, 2026, at a weighted average price of $21.61 per share. Following this transaction, he directly beneficially owns 32,044 common shares.
The purchase price reflects multiple trades executed in a range from $21.24 to $21.82 per share, as disclosed in the footnote. This filing documents increased personal share ownership by a senior executive through market purchases.
Tectonic Therapeutic, Inc. insider activity: Chief Business Officer Marc Schwabish reported a routine tax-related share withholding. On February 4, 2026, 1,619 shares of common stock were withheld by the company at $23.22 per share to cover his tax obligations from vesting restricted stock units granted on February 4, 2025. After this transaction, Schwabish directly beneficially owned 21,314 shares of Tectonic Therapeutic common stock.
Tectonic Therapeutic, Inc. reported that Chief Medical Officer Marcella K. Ruddy had 2,064 shares of common stock withheld on February 4, 2026. The company withheld these shares to cover her tax obligations related to the vesting and settlement of restricted stock units granted on February 4, 2025. After this tax withholding, she directly beneficially owned 53,247 common shares of Tectonic Therapeutic.
Tectonic Therapeutic, Inc. reported a routine share withholding related to its Chief Executive Officer, Alise Reicin. On February 4, 2026, the company withheld 4,104 shares of common stock at $23.22 per share to cover her tax obligations from vesting restricted stock units granted on February 4, 2025.
Following this transaction, Reicin beneficially owned 235,047 shares directly. An additional 124,530 shares were held indirectly through the Reicin-Boiarsky Family Trust, where she may share voting and dispositive power but disclaims full beneficial ownership beyond her economic interest.
Tectonic Therapeutic, Inc. insider Peter McNamara, Chief Scientific Officer, reported a routine share withholding related to equity compensation. On February 4, 2026, the issuer withheld 1,748 shares of common stock at $23.22 per share to cover his tax obligations on vested restricted stock units, leaving him with 39,131 directly held shares.
Tectonic Therapeutic, Inc.'s Chief Financial Officer, Daniel Lochner, reported a routine share withholding transaction. On February 4, 2026, the issuer withheld 2,077 shares of common stock at $23.22 per share to cover the officer’s tax obligations from vesting restricted stock units granted on February 4, 2025.
After this tax-related withholding, the reporting person directly beneficially owned 26,044 shares of common stock. This reflects administrative equity compensation activity rather than an open-market purchase or sale.